Brand name · Apomorphine hydrochloride
Apokyn: adverse event reports filed with FDA
5,274 reports list it as a suspect or interacting product, 2004–2026. Class: Dopaminergic agonist.
- 5,274
- reports as suspect product
- 0% of all reports · about 243 a year
- 188
- reports, 12 months to June 2026
- 292 in the 12 months before
- 24.1%
- marked serious by the reporter
- 33.2% across the class
- 5.8%
- record death among outcomes, as reported
- 307 reports · not verified by FDA
Between October 2004 and June 2026, 5,274 adverse event reports received by FDA list the brand name Apokyn (apomorphine hydrochloride) as a suspect or interacting product. Reports that mention it only as a concomitant medication (448) are left out of every figure here.
In the 12 months to June 2026, 188 reports listed it, down 36% from 292 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 243 reports a year and 0% of the 20,646,523 reports in the database, and 79.9% of the reports for the dopaminergic agonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are nausea (24.8%), somnolence (17.9%) and dizziness (13.5%). A report can list several reactions, so shares add to more than 100%; 428 different terms appear across these reports. Nausea is recorded in 24.8% of these reports, about the same share as in the median dopaminergic agonist drug (24.8%).
24.1% of the reports are marked serious by the reporter (33.2% across the class); 5.8% record death among the outcomes and 12.6% record hospitalisation, as reported. 76.6% of the reports came from consumers, and the largest patient age group is 65 to 74 (30.2%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Apokyn reports recording the termmedian drug in dopaminergic agonist
- Nauseafeeling sick24.8%1,307
- Somnolencedrowsiness17.9%946
- Dizzinesslight-headedness or unsteadiness13.5%712
- Falla fall9.5%499
- Yawning7.6%403
- Vomitingbeing sick6.9%364
- Blood pressure decreaseda low blood pressure reading5.9%313
- Drug ineffectivethe medicine did not work as expected5.8%305
- Dyskinesiainvoluntary movements5%263
- Hyperhidrosisexcessive sweating4.9%261
- Fatiguetiredness4.9%258
- Hypotensionlow blood pressure4.9%258
- Hallucinationseeing or hearing things that are not there4.9%257
- Feeling abnormalfeeling odd or not right4%211
- Deaththe patient died; cause not stated by this term3.4%177
- Malaisegeneral feeling of being unwell3.3%174
- Astheniaweakness or lack of energy3.3%172
- Headachehead pain3.2%169
- Injection site bruisingbruising where the injection was given3%158
- Tremorshaking3%156
- Rhinorrhoeaa runny nose2.7%141
- Confusional stateconfusion2.3%122
- Parkinson's disease2.3%120
- Blood pressure increaseda raised blood pressure reading2.2%116
- Dyspnoeashortness of breath2.1%113
- Loss of consciousnesspassing out2.1%113
- Gait disturbancedifficulty walking2%106
- Condition aggravatedthe condition being treated got worse1.8%97
- Syncopefainting1.8%94
- Therapy non-responderthe treatment did not work1.8%94
Top 30 of 428 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 3 drugs in the dopaminergic agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 6,603 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 97.6% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Parkinson's disease | 3,690 | 70% |
| Parkinson's disease | 215 | 4.1% |
| On and off phenomenon | 18 | 0.3% |
| Parkinsonism | 6 | 0.1% |
| Freezing phenomenon | 2 | 0% |
The indication field is filled in by the reporter and is often blank; shares are of all 5,274 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Apokyn reports |
|---|---|---|
| Sinemet | 876 | 16.6% |
| Rytary | 549 | 10.4% |
| Carbidopa levodopa | 441 | 8.4% |
| Carbidopa and levodopa | 434 | 8.2% |
| Amantadine | 327 | 6.2% |
| Azilect | 236 | 4.5% |
| Mirapex | 207 | 3.9% |
| Levodopa | 203 | 3.8% |
| Neupro | 196 | 3.7% |
| Gabapentin | 175 | 3.3% |
Other products listed in reports where Apokyn is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Apokyn | Dopaminergic agonist | All reports |
|---|---|---|---|
| Reports as suspect product | 5,274 | 6,603 | 20,646,523 |
| Share of that pool | — | 79.9% | 0% |
| Reports, latest 12 months | 188 | — | 1,332,454 |
| Marked serious | 24.1% | 33.2% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 58 | 58 | 91 |
| Hospitalisation recorded, per 1,000 reports | 126 | 163 | 213 |
| Consumer-filed share | 76.6% | 67.9% | 45.8% |
| Top term, share of reports | Nausea 24.8% | median 24.8% | 3.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the dopaminergic agonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Apomorphine hydrochloride | generic | 750 | 46 | 98.7% |
| Onapgo | brand | 579 | 568 | 32% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Apokyn reports
How many adverse event reports has FDA received for Apokyn?
5,274 reports list Apokyn as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 188 of them arrived in the latest 12 months. Another 448 list it only as a concomitant medication.
What reactions are recorded in Apokyn reports?
nausea (24.8%), somnolence (17.9%), dizziness (13.5%), fall (9.5%) and yawning (7.6%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Apokyn was responsible.
How serious are the reports?
24.1% are marked serious by the reporter. Among the outcomes recorded, 5.8% of reports include death and 12.6% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (76.6%), other health professional (14.8%) and not given (4.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Apokyn rising?
188 reports in the 12 months to June 2026, down 36% from 292 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Apokyn was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Apokyn?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Apokyn as a suspect or interacting product; reports listing it only as a concomitant medication (448) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.